Who are Low dose Oliceridine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Viberzi, Tapentadol Prolonged Release, Use of buprenorphine with FAO > 30 OME, opana then placebo then darvocet, High dose Oliceridine, TM buprenorphine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-oliceridine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Low dose Oliceridine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low dose Oliceridine (Low dose Oliceridine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mu-opioid receptor agonist. Area: Pain Management.

marketed Mu-opioid receptor agonist Mu-opioid receptor (OPRM1) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Low dose Oliceridine (Low dose Oliceridine) — Nanjing First Hospital, Nanjing Medical University. Low-dose oliceridine is a selective mu-opioid receptor agonist that provides analgesia with potentially reduced adverse effects compared to standard-dose opioids.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Low dose Oliceridine TARGET	Low dose Oliceridine	Nanjing First Hospital, Nanjing Medical University	marketed	Mu-opioid receptor agonist	Mu-opioid receptor (OPRM1)
Viberzi	ELUXADOLINE	AbbVie	marketed	mu-Opioid Receptor Agonist [EPC]	Mu-type opioid receptor	2015-01-01
Tapentadol Prolonged Release	Tapentadol Prolonged Release	Grünenthal GmbH	marketed	Mu-opioid receptor agonist and noradrenaline reuptake inhibitor	Mu-opioid receptor; noradrenaline transporter (NET)
Use of buprenorphine with FAO > 30 OME	Use of buprenorphine with FAO > 30 OME	Fox Chase Cancer Center	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
opana then placebo then darvocet	opana then placebo then darvocet	University of Rochester	marketed	Opioid analgesic (mu-opioid receptor agonist)	Mu-opioid receptor
High dose Oliceridine	High dose Oliceridine	Nanjing First Hospital, Nanjing Medical University	marketed	Mu-opioid receptor agonist (biased agonist)	Mu-opioid receptor (OPRM1)
TM buprenorphine	TM buprenorphine	Indivior Inc.	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (OPRM1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mu-opioid receptor agonist class)

Nanjing First Hospital, Nanjing Medical University · 1 drug in this class
Xiangya Hospital of Central South University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low dose Oliceridine — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-oliceridine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing